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INTRODUCTION
Alpha-ethyl-thioisonicotinamide (1314Th) was synthesized by D. Libermann
et aU), and has been found to be active against isoniazid (INH)-resistant, as
well as INH-susceptible tubercle bacilli both in vitro and in vivo.
And it has been widely used in the treatment of tuberculous cases in
whose sputa the tubercle bacilli had become resistant to streptomycin, PAS
and INH.
The writers also have been interested in 1314Th and carried out several
different investigations related to iF)3). It was found that 1314Th was fre-
quently badly tolerated by patients in poor condition, producing gastro-
intestinal symptoms (anorexia, nausea, gastralgia), renal and hepatic disturb-
ances etc.
Many attempts have been made to modify the structure of the 1314Th
to eliminate the side effects4 )5).
Alpha-ethyl-thioisonicotinamide-methanesulfonate (Th-S) is also one of the
derivatives of 1314Th, synthesized in the Dainippon Pharmaceutical Co. Ltd.,
and a water-soluble tuberculostatic compound. The chemical structure and
molecular weight of this compound are as follows:
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The writers were interested in Th-S and have done several funda-
mental and clinical trials with Th-S in order to study its antituberculous
activity and its side effects.
EXPERIMENTS
MATERIALS AND METHODS
I. Activity in vitro
Drugs: Drugs tested were Th-S and 1314Th.
Medium: Kirchner's liquid medium with 10 per cent bovine serum was
employed.
Inocula: Tenday-old culture of Mycobacterium tuberculosis var. hominis H37Rv
strain in Tween-albumin liquid medium was diluted with the same culture
medium to a concentration of about 1.0 mg. per mI., and agitated vigorously
with a pipette in a test tube. After the large clumps of bacilli had settled,
the supernatant of this initial suspension was diluted again with the same
culture medium to the final concentration of 0.2 mg. per mI. The final
bacillary suspension was dropped from Komagome's pipette into each test
tube (12 by 110 mm.), and the inoculum size was 0.01 mg. per ml. of medium.
Experimental procedures: Twofold duplicate serial dilutions of each drug
were made by successively transferring 2 ml. of Kirchner's medium. These
serial tubes and control tubes were inoculated with tubercle bacilli (H37Rv
strain). All tubes were incubated at 37Co. Four weeks later, all tubes were
examined and the minimum inhibitory concentration (MIC) of each drug was
recorded.
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II. Activity in vivo
1. Acute toxicity of the Th-S in mice:
Male albino mice (dd-strain) were used for the experiment. They weighed
14 to 16 g. when they were received at the laboratory. The mice were
housed in metal cages (not more than ten animals per cage) and were fed
with standard mouse pellets and water.
2. Activity in mice:
Male albino mice (dd-strain) were used for the experiment. Infection was
carried out by intravenous inoculation of 0.5 mg. of Mycobacterium tuberculosis
var. homnis Kurono strain.
Bacillary suspension was prepared from pellicles of 2 week-old cultures
of the strain on the surface of glycerin bouillon. The initial suspension was
diluted to a concentration of 5 mg. per ml. and the mice were inoculated
with 0.1 ml. of the final suspension.
Drugs: Th-S, 1314Th, INH, viomycin (VM), pyrazinamide (PZA), sulfisoxazole
(SI), cycloserine (CS), kanamycin (KM) and sodium o-aminophenol-methane-
sulfonate (SOM) were employed.
The administration of the drugs was started on the day following the
intravenous inoculation of tubercle bacilli and was continued until half of
the mice of anyone of the treated groups were dead. The number of dead
mice was plotted on a graph.
3. The tuberculostatic activity in the serum of humans after the administra-
tion of Th-S
The test doses of Th-S (400 mg. per person) and 1314Th (250 mg. per
person, powder and enteric coated tablets) were administered orally. The
blood samples for the test were collected aseptically before the drug-administ-
ration for the controls and 2, 4 and 6 hours after administration of the drugs
and allowed to stand for 24 hours. Then the serum was separated from these
samples by centrifugation, and modified Kirchner's medium added with serum
to the concentration of 90 per cent were prepared by Shioda's method6 ) for
this experiment. The medium thus obtained is composed of 0.1 m!. of modified
Kirchner's basic solution and 0.9 ml. of the serum. In the modified Kirchner's
basic solution, all ingredients were added to 10 times the original concentra-
tion.
Inocula: Ten day-old culture of Mycobacterium tuberculosis H37Rv strain in
Tween-albumin liquid media was diluted with saline solution to a con-
centration of about 0.5 mg. per ml. This suspension of bacilli was dropped
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by Komagome's pipette into each test tube (12 by 110 mm.), and the inoculum
size was 0.025 mg. per m!.
















add to 100.0 ml.
pH 6.2--6.4
I. Activity in vitro
Table 2 shows the tuberculostatic activity of 1314Th and Th-S. It was
found that 1314Th and Th-S inhibited the growth of Mycobacterium tuber-
culosis H37Rv in Kirchner's medium with 10 per cent bovine serum in con-
centrations ranging from 0.625 to 1.25 r per m!. The MIC of Th-S is somewhat
higher than that of 1314Th, but as the molecular weight of Th-S was 1.6
times that of 1314Th, the tuberculostatic activity of Th-S was almost equal
to that of 1314Th.
Table 2. Minimum Inhibitory Concentration of 1314Th and Th-S* (rim!.)




* Bacillary suspension was made from Tween-albumin culture of H37Rv strain.
Inoculum size was approximately 0.01 mg. per ml.
II. Activity in vivo
1. Acute toxicity of the Th-S in mice
The results are shown in table 3. It was found that the LD50 of Th-S
was 1240 mg. per kg. when the compound was administered orally, 1000 mg.
per kg. when the compound was injected subcutaneously, and 500 mg. per kg.
when injected intravenously. It appears the acute toxicity of Th-S is some-
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what less than that of 1314Th, but as the molecular weight of Th-S was 1.6
times that of 1314Th, the acute toxicity of Th-S showed almost equal to that
of the 1314Th if this is taken into consideration.
Table 3. Acute Toxicity in Mice: LD50 (mg. per kg.)
Calculated by Litchfield and Wilcoxon's Method7 )
Material Oral Subcutan. Intravenous.
--'~.~~._-_.,._--------~
1314Th 850 - -
-----
-_.- -
Th-S 1240 1000 500
2. Activity in mice
Influence of Th-S on the survival time (in days) of tuberculous mice was
observed.
a. Single administration of Th-S
Ninety mice were randomly divided into nine groups of ten mice each











10 mg. per kg. daily, intravenously
10 mg. per kg. daily, subcutaneously
10 mg. per kg. daily, orally
20 mg. per kg. daily, intravenously
20 mg. per kg. daily, subcutaneously
Fig. 2. Survival Rate of Tuberculous Mice Treated with 1314Th
and Th-S
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Numerals in parenthesis indicate mean survival time in days.
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20 mg. per kg. daily, orally
1 mg. per kg. daily, orally
10 mg. per kg. daily, orally
(untreated)
Treatment was discontinued on the twenty-first day after the inoculation.
The survival rates of these groups are shown in figure 2. Th-S 10 mg. per kg.
orally showed the same therapeutic effect as 1314Th 10 mg. per kg. orally.
Of the routes of drug-administration, subcutaneous injection was the most
effective, next, intravenous injection, and oral administration was the least
effective, but there was no significant difference among them.
b. Single administration of Th-S when the dose was decreased












10 mg. per kg. daily, orally
5 mg. per kg. daily, orally
16 mg. per kg. daily, intravenously
8 mg. per kg. daily, intravenously
(untreated)
Treatment was discontinued on the fourteenth day after the inoculation.
The survival rates of these groups are shown in figure 3.
Th-S 16 mg. per kg. intravenously showed better therapeutic effect than
that of 1314Th 10 mg. per kg. orally. But when the dose of Th-S was de-
creased, Th-S 8 mg. per kg. intravenously showed almost same therapeutic
effect as 1314Th 5 mg. per kg. orally.
c. Combined administration of Th-S with other antituberculous drugs
Ninety mice were randomly divided into nine groups of ten mice each









16 mg. per kg. daily, intravenously
8 mg. per kg. daily, intravenously
8 mg. per kg. daily, intravenously and
20 mg. per kg. twice a week, subcutaneously
8 mg. per kg. daily, intravenously and
30 mg. per kg. daily, orally
8 mg. per kg. daily, intravenously and
30 mg. per kg. daily, orally
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Numerals in parenthesis indicate mean survival lime in clays.
Fig. 4. Survival Rate of Tuberculous Mice Treated with Th-S
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8 mg. per kg. daily, intravenously and
5 mg. per kg. daily, orally
8 mg. per kg. daily, intravenously and
20 mg. per kg. twice a week, subcutaneously
8 mg. per kg. daily, intravenously and
20 mg. per kg. daily, orally
(untreated)
Treatment was discontinued on the fifteenth day after the inoculation.
Survival rates of these groups are shown in figure 4.
Th-S 16 mg. per kg. intravenously showed considerable effect. Then, in
the experiment on the combined therapy the dose of Th-S was decreased to
one half.
The combined treatment of Th-S with viomycin, pyrazinamide, sulfisoxa-
zole, cycloserine, kanamycin and with o-aminophenol-methanesulfonate were
compared with that of Th-S alone.
The treatment with Th-S 8 mg. per kg. and CS 5 mg. per kg., and with
Th-S 8 mg. per kg. and KM 20 mg. per kg. were a little more effective than that
with Th-S 8 mg. per kg. alone, but they were not as effective as Th-S 16 mg.
per kg. alone.
3. The tuberculostatic activity in the serum of human after the administ-
ration of Th-S
Fig. 5. Duration in Hour of Bacteriostatic Activity of Serum
after Administration of Drug
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As shown in Fig. 5, the tuberculostatic activity of the serum when Th-S
was given orally was recognized up to 2 to 4 hours after administration, and
this tuberculostatic activity seemed to appear earlier than that of 1314Th
enteric coated tablet given orally.
CLINICAL TRIALS
As 1314Th was often poorly tolerated, producing gastrointestinal symp-
toms, the writers attempted intravenous drip of Th-S to the patients who
poorly tolerated oral 1314Th. Th-S was dissolved in 300 ml. of physiological
saline solution and was injected intravenously over about 3 hours.
The results were illustrated in table 4. The side effects (nausea, vomiting,
headache, vertigo, etc.) were still fairly often, and of 43 patients, in 13 (34.9
per cent) the injection had to be discontinued within 1 month, 17 (39.5 per
cent) within 2 months, 24 (55.8 per cent) within 3 months, 28 (65.1 per cent)
within 4 months, and only 15 (34.9 per cent) tolerated the intravenous drip of
Th-S well.
Thus the gastrointestinal side effects of 1314Th as well as Th-S were
considered due to the injury after absorption.
The writers attempted to get the low but sustaining blood level of the
drug. Of course the writers can not deny the possibility of the gastro-
intestinal side effects of 1314Th due to direct injury on stomach wall, but
following their experience the enteric coated tablets of 1314Th were some-
times found in feces. So firstly 50 mg. of non enteric-coated 1314Th was
administered orally 10 times a day and in the intolerated cases 25 mg. of
1314Th was administered 12 times a day.
The results were illustrated in table 5. In this case, side effects were
relatively few, and of 112 patients, in only 33 (29.5 per cent) the administra-
tion had to be discontinued within 4 months.
Then, the writers attempted the divided administration of Th-S to the
patients who had to be discontinued the administration of 1314Th.
800 mg. (daily dose) of Th-S corresponds to 500 mg. of 1314Th, and 500 mg.
of Th-S corresponds to 300 mg. of 1314Th. 80 mg. or 50 mg. (in the intolerated
cases) of Th-S was administered orally ten times a day.
The results were illustrated in table 6. And of the 24 patients, in 17
(70.8 per cent) the administration was well tolerated for 4 months.
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Table 5. Side Effects of 50 mg. of 1314Th (Non Enteric-Coated)
Administered 10 Times a Day or at least 25 mg. of









Table 6. Side Effects of 80 mg. or 50 mg. of Th-S (Taking into











The present investigations show that Th-S has a certain antituberculous
activity.
The writers observed that the minimum inhibitory concentration of Th-S
against the strain (H37Rv) in Kirchner's liquid medium containing 10 per cent
bovine serum proved to 1.25 r per ml. The MIC of TH-S is somewhat higher
than that of 1314Th, but if the molecular weight of Th-S is taken into con-
sideration, the tuberculostatic activity of Th-S is almost equal to 1314Th.
The acute toxicity in mice and activity in mice were investigated, and LD50
was found to be 1240 mg. per kg. when the compound was administered
orally, 1000 mg. per kg. when injected subcutaneously, and 500 mg. per kg. by
intravenous injection. And if the molecular weight of Th-S was taken into
consideration, there was no significant difference found between 1314Th and
Th-S. In the experiments on mice, the therapeutic effect of Th-S showed
the same good therapeutic effect of 1314Th.
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The tuberculostatic activity in the human serum after administration of
Th-S was investigated. This tuberculostatic activity was seemed to appear
a little earlier than that of enteric-coated 1314Th given orally.
Up to this point, there is no significant difference in antituberculous
activity between 1314Th and Th-S. Then the intravenous drip of Th-S was
tried and found to be ineffective to decrease the side effects. But the divided
administration of non enteric-coated 1314Th was investigated with good re-
sults. At last the best results were obtained in the use of divided administ-
ration of Th-S. But the influence of the divided administration of 1314Th or
Th-S on their therapeutic effects has not been settled yet. This problem is
now being examined in animals.
SUMMARY
Observations were presented on the activity in vitro and in vivo of
alpha-ethyl-thioisonicotinamide-methanesulfonate (Th-S). This compound is a
water-soluble substance. The molecular weight of Th-S is 262.3, 1.6 times
that of 1314Th (166.2).
1. The minimum inhibitory concentration (MIC) of Th-S against H37Rv
strain in Kirchner's liquid medium with 10 per cent bovine serum, proved to
be 1.25 r per ml.
2. The toxicity of Th-S in mice was tested, and LD50 was found to be
1240 mg. per kg. when the compound was administered orally, 1000 mg. per kg.
when injected subcutaneously, and 500 mg. per kg. by intravenous injection.
3. Mice infected with tubercle bacilli of human origin (Kurono strain)
were employed. In this experiment, the therapeutic effect of Th-S showed
the same good therapeutic effect of 1314Th.
4. The tuberculostatic activity of the serum when Th-S was given orally
was recognized up to 2 to 4 hours after administration, and this tuberclostatic
activity seemed to appar earlier than that of 1314Th enteric-coated tablet
given orally.
5. The writers attempted intravenous drip of Th-S to patients poorly
tolerating 1314Th. The side effects were still fairly often. Divided oral
administration of Th-S was better tolerated than that of 1314Th by these
patients.
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